Announcement • May 23

Teleflex Incorporated Showcases New Clinical Data on Urolift System and Barrigel Rectal Spacer

Teleflex Incorporated announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift System and Barrigel rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Data presented at the 2026 American Urological Association (AUA) Annual Meeting in Washington, DC. May 15 – 18 and the European Society for Radiotherapy & Oncology (ESTRO) Congress held in Stockholm May 15 – 19 highlight early patient experience following BPH treatment with the UroLift System and sustained reductions in radiation-associated toxicity for prostate cancer patients who received Barrigel rectal spacer. At AUA 2026, 12-month findings from the CLEAR (Comparing UroLift Experience Against Rezum) randomized controlled trial, the first prospective, multicenter, head-to-head RCT comparing MISTs for BPH, were presented. The study evaluated key endpoints including catheter independence, symptom improvement, patient experience, and sexual function. Catheter independence from day three through day seven was significantly better among UroLift System patients compared to Rezum patients, with 3% requiring catheter versus 20% (p=.02) respectively. Early patient experience was better for the UroLift System patients compared to Rezum patients. UroLift System and Rezum subjects had similar durability through 12 months. Patients’ sexual function was preserved through 12 months with the UroLift System. At ESTRO 2026, new three-year outcomes highlighted the long-term safety and effectiveness of Barrigel rectal spacer. Patients in the Barrigel rectal spacer arm of the study experienced a continued Grade 2+ toxicity benefit sustained through three years. Zero percent of the Barrigel rectal spacer patients experienced Grade 2+ toxicity versus 10% in the control arm. Fewer patients with greater than one centimeter of apical spacing had a decline in bowel quality of life at 36 months versus control. The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift System permanent implants, which can be delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction. A study conducted over five years showed a low retreatment rate of about 2% to 3% per year, or a total of 13.6% over the course of the study, demonstrating UroLift System durability. Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift System in select markets worldwide. The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 45 years or older with prostates =100 cc. Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence due to incompetent sphincter, and urethral conditions that prevent device insertion. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. Barrigel rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer. Barrigel rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA). Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide. Barrigel rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy and is cleared for rectal spacing in the United States, Australia, and Europe. Barrigel rectal spacer is indicated for prostate cancer patients with T1-T3b disease. Barrigel rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, the intent is to reduce the radiation dose delivered to the anterior rectum. It is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time. It should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area. Potential complications include but are not limited to: pain associated with the injection; needle penetration or injection of Barrigel rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. Contraindicated in prostate cancer patients with clinical stage T4 disease. Individual results may vary.

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	5yrs
Board average tenure	6.4yrs

Name	Position	Tenure	Compensation	Ownership
John Deren	Executive VP & CFO	1.3yrs	US$2.11m	0.0042% € 220.8k
Daniel Logue	Corporate VP	5.5yrs	US$1.60m	0.028% € 1.5m
Cameron Hicks	Corporate Vice President of Human Resources & Communications	13.3yrs	US$1.35m	0.021% € 1.1m
Jason Weidman	President	less than a year	no data	no data
Timothy Duffy	VP & Chief Information Officer	no data	no data	no data
Lawrence Keusch	Vice President of Investor Relations & Strategy Development	no data	no data	no data
Howard Cyr	Corporate VP & Chief Compliance Officer	4.7yrs	no data	no data
Matt Tomkin	Vice President of Corporate Development	4.4yrs	no data	no data
James Ferguson	President & GM of Surgical	no data	no data	no data
Matthew James	President & GM of Interventional	6.1yrs	no data	no data
Jake Newman	President & GM of Vascular and Emergency Medicine	5.4yrs	no data	no data
Kevin Robinson	President & GM of Anesthesia and Emergency Medicine	no data	no data	no data

Name	Position	Tenure	Compensation	Ownership
Jason Weidman	President	less than a year	no data	no data
Gretchen Frances Haggerty	Independent Director	9.8yrs	US$318.05k	0.014% € 746.9k
Michael Tokich	Independent Director	less than a year	no data	no data
Stuart Randle	Director	17.2yrs	US$340.55k	0.0072% € 379.7k
Andrew Krakauer	Independent Chairman	8.5yrs	US$318.08k	0.016% € 855.5k
Candace Duncan	Independent Director	11.2yrs	US$341.55k	0.013% € 704.9k
Jaewon Ryu	Independent Director	3.2yrs	US$318.05k	0.0084% € 441.6k
Neena Patil	Independent Director	4.3yrs	US$314.05k	0.0059% € 311.0k

Data	Last Updated (UTC time)
Company Analysis	2026/07/23 00:22
End of Day Share Price	2026/07/23 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Matthew Taylor	Barclays
Vikramjeet Chopra	BMO Capital Markets Equity Research
Travis Steed	BofA Global Research

Teleflex Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Teleflex Incorporated Announces President Changes

Teleflex Incorporated, Annual General Meeting, May 15, 2026

Teleflex Incorporated Announces Board Changes

Insufficient new directors

Recent updates

Teleflex Incorporated to Report Q2, 2026 Results on Aug 06, 2026

New major risk - Share price stability

Teleflex Initiates Enrollment in Global Biomag-III Pivotal Trial of Freesolve Resorbable Magnesium Scaffold

Insufficient new directors

Teleflex Incorporated Showcases New Clinical Data on Urolift System and Barrigel Rectal Spacer

Teleflex Incorporated Announces Quarterly Dividend, Payable on June 30, 2026

Teleflex Incorporated Maintains Earnings Guidance for the Year 2026

New major risk - Revenue and earnings growth

Insufficient new directors

Teleflex Incorporated Announces President Changes

Teleflex Incorporated, Annual General Meeting, May 15, 2026

Teleflex Incorporated Announces Board Changes

Irenic Capital Sends a Letter to Teleflex Board

Full year 2025 earnings released: EPS: US$1.31 (vs US$1.22 in FY 2024)

Teleflex Announces Quarterly Dividend, Payable on March 31, 2026

Insufficient new directors

Insufficient new directors

Teleflex Incorporated Announces CEO Changes

Insufficient new directors

Montagu Private Equity LLP and Kohlberg & Company, L.L.C. agreed to acquire Teleflex Medical OEM from Teleflex Incorporated (NYSE:TFX) for $1.5 billion.

Dividend of US$0.34 announced

Teleflex Incorporated Narrows Earnings Guidance for the Year 2025

Third quarter 2025 earnings released: US$9.24 loss per share (vs US$2.37 profit in 3Q 2024)

Teleflex Incorporated Announces Quarterly Cash Dividend, Payable on December 15, 2025

Insufficient new directors

Insufficient new directors

Teleflex Incorporated Announces the Enrollment of the First Patient in the DUBSTENT DIABETES trial

Teleflex Incorporated Announces the Launch of Barrigel Rectal Spacer in Japan as A Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy

Teleflex Incorporated Declares Quarterly Cash Dividend on Common Stock, Payable September 15, 2025

Teleflex Incorporated (NYSE:TFX) completed the acquisition of Substantially all of the Vascular Intervention Business from BIOTRONIK SE & Co. KG.

Teleflex Incorporated Announces New Prospective Cohort Study Reporting the Efficacy of Arrow Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

Teleflex Incorporated Showcases New Clinical Data Presented At the 2025 American Urological Association Annual Meeting

Teleflex Incorporated Announces the Publication of New Retrospective Analysis of Clinical Data

Teleflex Incorporated Announces Quarterly Dividend, Payable on June 16, 2025

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources